# AstraZeneca: Observational study closed enrollment, 625 enrolled (Breast Cancer)

**Score:** 60/100

| Field | Value |
|---|---|
| Sponsor | AstraZeneca |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Non-interventional Prospective Study of Early HER2-negative High-risk Breast Cancer and BRCA1/2 Mutations Prevalence in RussiA |
| NCT ID | NCT05939128 |
| Phase | Observational |
| Status | active not recruiting |
| Conditions | Breast Cancer |
| Target enrollment | 625 |
| Site countries | Russia |
| Posted | 2023-07-11 |
| Planned start | 2023-06-30 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-02 |
| Last update posted | 2026-10-02 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- 625 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05939128). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.